China Resources Boya Bio-pharmaceutical Issues Sharp 2025 Profit Warning Amid Aesthetics Slump
China Resources Boya Bio-pharmaceutical, a key player in blood products and medical aesthetics, has flagged a dramatic profit decline for 2025, projecting net profit attributable to shareholders at
